Haemonetics Corp. (NYSE:HAE) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $36.87 and last traded at $36.84, with a volume of 247,600 shares changing hands. The stock had previously closed at $36.30.

A number of brokerages recently issued reports on HAE. Morgan Stanley restated a “hold” rating on shares of Haemonetics Corp. in a report on Tuesday, May 3rd. Barrington Research reduced their price target on shares of Haemonetics Corp. from $40.00 to $32.00 and set an “outperform” rating for the company in a report on Tuesday, May 3rd. Benchmark Co. upped their price target on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the company a “hold” rating in a report on Tuesday, August 2nd. Goldman Sachs Group Inc. upgraded shares of Haemonetics Corp. from a “sell” rating to a “neutral” rating and set a $29.00 price target for the company in a report on Monday, May 16th. Finally, Zacks Investment Research cut shares of Haemonetics Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has issued a buy rating to the stock. Haemonetics Corp. has a consensus rating of “Hold” and an average price target of $34.40.

The company has a 50-day moving average of $33.26 and a 200 day moving average of $31.68. The firm’s market capitalization is $1.89 billion.

Haemonetics Corp. (NYSE:HAE) last issued its quarterly earnings data on Monday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $210 million for the quarter, compared to analyst estimates of $205.41 million. Haemonetics Corp.’s revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.35 EPS. On average, equities analysts forecast that Haemonetics Corp. will post $1.44 EPS for the current fiscal year.

In other Haemonetics Corp. news, CEO Christopher Simon acquired 60,000 shares of the company’s stock in a transaction that occurred on Thursday, August 4th. The stock was acquired at an average price of $35.00 per share, for a total transaction of $2,100,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronald Merriman sold 4,337 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the completion of the transaction, the director now owns 22,088 shares of the company’s stock, valued at approximately $776,172.32. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Haemonetics Corp. stock. Principal Financial Group Inc. boosted its stake in Haemonetics Corp. (NYSE:HAE) by 5.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 344,105 shares of the company’s stock after buying an additional 16,768 shares during the period. Principal Financial Group Inc. owned 0.68% of Haemonetics Corp. worth $11,094,000 as of its most recent filing with the SEC.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.